GBZ 67-2002 Occupational beryllium disease diagnostic criteria

This standard specifies the diagnostic criteria and treatment principles for occupational beryllium disease. This standard applies to acute or chronic beryllium disease caused by exposure to dust and smoke of metallic beryllium, beryllium oxide, beryllium carbonate, beryllium fluoride, beryllium hydroxide and other beryllium compounds in the beryllium smelting industry, beryllium processing and beryllium scientific research and experiments. GBZ 67-2002 Occupational Beryllium Disease Diagnostic Criteria GBZ67-2002 Standard Download Decompression Password: www.bzxz.net

ICS13.100
National Occupational Health Standard of the People's Republic of China GBZ67-2002
Diagnostic Criteria of Occupational Beryllium Disease2002-04-08 Issued
2002-06-01 Implementation
Ministry of Health of the People's Republic of China
Article 6.1 of this standard is recommended, and the rest are mandatory. This standard is formulated in accordance with the "Law of the People's Republic of China on the Prevention and Control of Occupational Diseases". From the date of implementation of this standard, if there is any inconsistency between the original standard GB4868-1996 and this standard, this standard shall prevail. Beryllium disease may be caused in occupational activities involving contact with beryllium. In order to protect the health of workers, facilitate the prevention and control of poisoning, and in accordance with the requirement that the diagnostic standards for occupational diseases should reflect the latest clinical progress, GB4868-1996 has been revised. The revised version of this standard has made clear provisions for the X-ray diagnosis of occupational beryllium disease and deleted the laboratory test methods in the original standard. This makes the standard more practical. Appendix A of this standard is an informative appendix.
This standard is proposed and managed by the Ministry of Health of the People's Republic of China. This standard is drafted by the Labor Protection Research Institute of China Nonferrous Metals Industry Corporation. This standard is interpreted by the Ministry of Health of the People's Republic of China. ..comOccupational plating disease diagnosis standard
GBZ67-2002
Plate disease is a systemic disease caused by exposure to beryllium and its compounds, mainly respiratory damage. After inhaling high concentrations of beryllium or its compounds in a short period of time, the lesions mainly characterized by acute chemical inflammation of the respiratory tract are called acute beryllium disease. After being exposed to beryllium and its compounds, after a certain incubation period, the lesions mainly characterized by pulmonary granulomas and pulmonary interstitial fibrosis occur, which is called chronic beryllium disease. 1
This standard specifies the diagnostic criteria and treatment principles for occupational beryllium disease. This standard applies to acute or chronic beryllium disease caused by exposure to metal beryllium, beryllium oxide, beryllium carbonate, beryllium fluoride, beryllium hydroxide and other beryllium compounds in the beryllium smelting industry, beryllium processing and beryllium scientific research and experiments. 2 Normative references
The clauses in the following documents become the clauses of this standard through reference in this standard. For all dated referenced documents, all subsequent amendments (excluding errata) or revised versions are not applicable to this standard. However, the parties to the agreement based on this standard are encouraged to study whether the latest versions of these documents can be used. For all undated referenced documents, the latest versions shall apply to this standard.
3 Diagnostic principles
Diagnostic criteria for pneumoconiosis
Diagnostic criteria for occupational skin diseases (general principles) Based on a clear history of occupational exposure and clinical manifestations mainly in the respiratory system and chest X-ray signs, refer to the work environment hygiene survey and on-site air beryllium concentration measurement data, conduct a comprehensive analysis, and exclude other similar diseases before diagnosis. 4 Observation subjects
May have symptoms such as chest tightness and cough. Chest X-rays show irregular small shadows and a few small granular shadows scattered in one lung area (the density is less than 10 within a range of 2cm and occupies less than 2/3 of the lung area). 5 Diagnosis and grading standards
5.1 Chronic beryllium disease
5.1.1 Mild
There are chest tightness, cough, and shortness of breath during activities. Chest X-rays show irregular small shadows and a large number of small granular shadows in lung areas 1 to 4 (the density is more than 10 within a range of 2cm and occupies more than 2/3 of the lung area). 5.1.2 Severe
Symptoms of chest tightness and chest pain are obvious, and there is shortness of breath or difficulty breathing when at rest, purple veil phenomenon, and the chest X-ray shows small granular shadows distributed in more than four lung areas on the basis of mild manifestations. 5.2 Acute beryllium disease
5.2.1 MildWww.bzxZ.net
Symptoms of respiratory irritation such as dry pain in the nasopharynx, severe cough, chest discomfort, etc., and chest X-rays may show enhanced, distorted and disordered lung textures.
..com5.2.2 Severe
Shortness of breath, cough, sputum, hemoptysis, fever, and moist rales can be heard in the lungs. Chest X-rays show diffuse cloud-like or patchy shadows in the lung fields, and sometimes pulmonary edema, respiratory failure or other organ damage may occur. 6 Treatment principles
6.1 Treatment principles
6.1.1 Chronic beryllium disease
In addition to symptomatic and supportive treatment, adrenal glucocorticoid drugs can be used according to the condition. 6.1.2 Acute beryllium disease
The patient should leave the scene quickly. Remove pollutants from the body surface and clothes. For mild cases, symptomatic treatment is given. For severe cases, adrenal glucocorticoid drugs can be used as early as possible in addition to routine medical treatment. 6.2 Other treatments
6.1.1 Observation subjects
Generally, they are not transferred from beryllium operations and are closely observed clinically for two years (chest X-rays are taken every six months). If there is no progression of the disease, regular health examinations are arranged according to the requirements of beryllium operators. 6.1.2 Chronic beryllium disease
The patient should be transferred from beryllium operations and other dust operations. For mild cases, appropriate work can be arranged, and for severe cases, hospitalization and recuperation are required. 6.1.3 Acute beryllium disease
After treatment, in principle, no longer engage in beryllium work. Close observation should be carried out, and chest X-ray examination should be carried out every six months. If there is no change for two consecutive years, dynamic observation can be carried out as a beryllium worker. 7 Instructions for the correct use of this standard
See Appendix A (Informative Appendix).
..com Appendix A
(Informative Appendix)
Instructions for the correct use of this standard
A.1 This standard applies to personnel who are exposed to metal beryllium, beryllium oxide, beryllium sulfate, beryllium carbonate, beryllium fluoride, beryllium hydroxide and other beryllium compounds in beryllium smelting industry and beryllium processing, as well as scientific research and experiments. A.2 Skin damage caused by beryllium refers to GBZ70, but it is not included in the diagnostic criteria for occupational beryllium disease. A.3 X-ray chest radiographs are the main basis for diagnosing beryllium disease. Chest radiographs should meet quality requirements before they can be used [refer to Appendix C (Normative Appendix) of GBZ70]. The small granular shadows referred to in the standard include nodular shadows (25 mm in diameter) and granular shadows (about 1 mm in diameter).
A.4 When diagnosing this disease, attention should be paid to distinguishing it from the following diseases: miliary tuberculosis, pulmonary schistosomiasis, hemosiderosis, pneumoconiosis, sarcoidosis, alveolar carcinoma, pulmonary microlithiasis and nonspecific pulmonary interstitial fibrosis.
5 Specific immune indicators with beryllium as antigen and beryllium skin patch test are of great significance for the differential diagnosis of chronic beryllium disease. In the revised version of A.5
, it is not included in the diagnostic indicators.
Tip: This standard content only shows part of the intercepted content of the complete standard. If you need the complete standard, please go to the top to download the complete standard document for free.